A Small Change Can Make a Big Difference: A Lesson from Evolocumab.

doi:10.1016/j.hlc.2018.03.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Small Change Can Make a Big Difference: A Lesson from Evolocumab.

Heart, lung & circulation - 1 Mar 2019

Mirzaee Sam, Thein Paul M, Wong Dennis, Nasis Arthur

Abstract excerpt

BACKGROUND: Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes in high risk patients. METHODS: This is a case study describing a stepwise approach to "PCSK9 inhibitor non-response" in a patient with familial hypercholesterolaemia. There are a few described pathophysiological mechanisms for "PCSK9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Anticholesteremic Agents
Share to Coronary Artery Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Electrocardiography

Share to Hyperlipoproteinemia Type II

Share to Injections, Subcutaneous

Share to Proprotein Convertase 9

Source

Open in PubMed

Identifiers

PMID: 29685715
DOI: 10.1016/j.hlc.2018.03.009

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.